ChiRex hosts international technical symposium on recent advances in chiral technology; In conjunction with dedication of ChiRex's new R&D and Pilot Plant facilities.DUDLEY, UK--(BUSINESS WIRE)--July 1, 1996--ChiRex hosted today a prestigious, by invitation only, technical symposium on recent advances in chiral chi·ral adj. Of or relating to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. chi·ral technologies to produce single-isomer fine chemicals and bulk active drugs, at Gosforth Park Hotel, Newcastle, UK. Dr. Robert L. Bratzler, ChiRex's Chairman and Chief Executive Officer, introduced the symposium, which was organized to celebrate the opening of the $13.5 million R&D Center for cGMP pharmaceutical fine chemical development at its Dudley, Northumberland, United Kingdom site. There were 80 attendees made up of senior scientific representatives from 20 major international pharmaceutical companies including Astra, British Biotech British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] , Eli Lilly Eli Lilly can refer to:
The speakers consisted of members of the ChiRex Scientific Advisory Board - Professors Barry Sharpless - The Scripps Research Institute (La Jolla, California, USA), Eric Jacobsen - Harvard University (Cambridge, Massachusetts, USA), Stephen Buchwald - MIT MIT - Massachusetts Institute of Technology (Cambridge, Massachusetts, USA); and internationally acclaimed UK scientists: Professors Sandy McKillop - (The University of East Anglia “UEA” redirects here. For other uses, see UEA (disambiguation). Academically, it is one of the most successful universities founded in the 1960s, consistently ranking amongst Britain's top higher education institutions; 19th in the Sunday Times University League Table 2006 at Norwich, UK), and Stanley Roberts - (Liverpool University UK). Dr. Sharpless outlined his new advanced technologies for the production of single-isomer amino alcohols by catalytic asymmetric aminohydroxylation. ChiRex holds the worldwide exclusive rights to the catalyst and chiral ligand used in this technology and other patent applications are pending. One advantage of this technology is that relatively inexpensive feedstocks can be converted cost effectively to single-isomer fine chemicals used in the production of many different drugs including new drugs to combat AIDS and Cancer. Dr. Jacobsen discussed the latest advances from his Harvard laboratories on a process called catalytic asymmetric nucleophile nucleophile Atom or molecule that contains an electron pair available for bonding and in chemical reactions therefore seeks a positive centre, such as the nucleus of an atom or the positive end of a polar molecule (see covalent bond; electric dipole). . This process is effective in the manufacture of a wide variety of single-isomer epoxides such as epichlorohydrin ep·i·chlo·ro·hy·drin n. A colorless liquid, C3H5OCl, used as a solvent in making resins. , a fine chemical building block used in drug manufacture. ChiRex holds the exclusive worldwide license rights for the catalyst used in this technology. Patent Issued ChiRex announced the issuance of US Patent 5,516,929 Method for Catalytic Asymmetric Dihydroxylation of Olefins using Heterocyclic heterocyclic /het·ero·cyc·lic/ (het?er-o-sik´lik) having a closed chain or ring formation including atoms of different elements. het·er·o·cy·clic adj. Chiral Ligands by Sharpless et al., which is assigned to MIT and exclusively licensed to ChiRex. This patent covers methods for the production of single isomer isomer (ī`səmər), in chemistry, one of two or more compounds having the same molecular formula but different structures (arrangements of atoms in the molecule). Isomerism is the occurrence of such compounds. diols and derivatives useful in drug manufacture. This brings ChiRex issued patents to 38, with 16 other patents pending. ChiRex Inc. manufactures and sells pharmaceutical fine chemicals. With some 50 patents and patent applications in the field of chiral technology, ChiRex is a leader in the technologies for the production of single-isomer fine chemicals. Over 50 different fine chemical drug products are manufactured at its Dudley, UK facilities and, through its joint venture company, InNova Pharmaceuticals, ChiRex also manufactures and sells formulated generic drugs. InNova's first product is paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , useful in the treatment of ovarian and breast cancer. CONTACT: Robert L. Bratzler, Ph.D. Chairman and Chief Executive Officer OR Michael A. Griffith Vice President and Chief Financial Officer (617) 431-2200 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion